A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 93-101

  Hellwig, Anne ^a   Scherber, Anja ^a   Koehler, Carsta ^a   Hanefeld, Markolf ^a   Henle, Thomas ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

diabetic complications; fructosamine 3 kinase (FN3K); fructosamine 3 kinase related protein (FN3K RP); glycation

Indexed keywords

FRUCTOSAMINE 3 KINASE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYL GROUP; LIPID; PHOSPHOTRANSFERASE; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DENATURATION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ERYTHROCYTE; FAMILY HISTORY; FATTY LIVER; FEMALE; GALLSTONE; GLUCOSE TOLERANCE; GLYCATION; HEMOLYSATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC DISORDER; MICHAELIS MENTEN KINETICS; MIDDLE AGED; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ERYTHROCYTES; FEMALE; HEXOSES; HUMANS; LYSINE; MALE; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SUBSTRATE SPECIFICITY;

EID: 84891458553     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0853     Document Type: Article

References (31)

1. Fujita T, Suzuki K, Tada T, Yoshihara Y, Hamaoka R, Uchida K, et al. Human erythrocyte bisphosphoglycerate mutase: inactivation by glycation in vivo and in vitro. J Biochem 1998;124:1237-44.
2. Van Schaftingen E, Collard F, Wiame E, Veiga-da-Cunha M. Enzymatic repair of Amadori products. Amino Acids 2012;42:1143-50.
3. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. ?-Oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 2003;31:1358-63.
4. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008;40:553-624.
5. Collard F, Vertommen D, Fortpied J, Duester G, Van Schaftingen E. Identification of 3-deoxyglucosone dehydrogenase as aldehyde dehydrogenase 1A1 (retinaldehyde dehydrogenase 1). Biochimie 2007;89:369-73.
6. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buysschaert M, van Schaftingen E. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 2006;32:31-9.
7. Veiga-da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Theate I, Vertommen D, et al. Increased protein glycation in fructosamine-3-kinase deficient mice. Biochem J 2006;399: 257-64.
8. Mosca L, Penco S, Patrosso MC, Marocchi A, Lapolla A, Sartore G, et al. Genetic variability of the fructosamine 3-kinase gene in diabetic patients. Clin Chem Lab Med 2011;49:803-8.
9. Mohás M, Kisfali P, Baricza E, Mérei A, Maasz A, Cseh J, et al. A polymorphism within the fructosamine-3-kinase gene is associated with HbA1c levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2009;118:209-12.
10. Pácal L, Tanhäuserová V, Svojanovský J, Krusová D, Št?pánková S, Olšovský J, et al. Does genetic variability in the fructosamine-3-kinase play a role in the progression of diabetic nephropathy, morbidity and mortality of diabetics? Diabetologia 2010;53:S135.
11. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229-39.
12. Collard F, Delpierre G, Stroobant V, Matthijs G, van Schaftingen E. A mammalian protein homologous to fructosamine-3-kinase is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 2003;52:2888-95.
13. Fortpied J, Gemayel R, Vertommen D, Van Schaftingen E. Identification of protein-ribulosamine-5-phosphatase as human low-molecular-mass protein tyrosine phosphatase-A. Biochem J 2007;406:139-45.
14. Takahashi S, Izawa Y, Suzuki N. Astroglial pentose phosphate pathway rates in response to high-glucose environments. ASN Neuro 2012;4:71-88.
15. Cappai G, Songini M, Doria A, Cavallerano JD, Lorenzi M. Increased prevalence of proliferative retinopathy in patients with type 1 diabetes who are deficient in glucose-6-phosphate dehydrogenase. Diabetologia 2011;54:1539-42.
16. Kunjara S, Greenbaum AL, Sochor M, Ali M, Flyvbjerg A, Gronbaek H, et al. Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes. Int J Exp Pathol 2012;93:56-69.
17. Szwergold BS, Manevich Y, Payne L, Loomes K. Fructosamine-3-kinase- related-protein phosphorylates glucitolamines on the C-4 hydroxyl: novel substrate specificity of an enigmatic enzyme. Biochem Biophys Res Commun 2007;361:870-5.
18. Delplanque J, Delpierre G, Opperdoes FR, van Schaftingen E. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. J Biol Chem 2004;279:46606-13.
19. Krause R, Oehme A, Wolf K, Henle T. A convenient HPLC assay for the determination of fructosamine-3-kinase activity in erythrocytes. Anal Bioanal Chem 2006;386:2019.
20. Hodge JE, Fisher BE. Amadori rearrangement products. Methods Carbohydr Chem 1963;2:99-107.
21. Collard F, Wiame E, Bergans N, Fortpied J, Vertommen D, Vanstapel F, et al. Fructosamine 3-kinase-related protein and deglycation in human erythrocytes. Biochem J 2004;382: 137-43.
22. Delpierre G, Vanstapel F, Stroobant V, van Schaftingen E. Conversion of a synthetic fructosamine into its 3-phospho derivative in human erythrocytes. Biochem J 2000;352:835-9.
23. Conner JR, Beisswenger PJ, Szwergold BS. The expression of the genes for fructosamine-3-kinase and fructosamine-3-kinaserelated protein appears to be constitutive and unaffected by environmental signals. Biochem Biophys Res Commun 2004;323:932-6.
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
25. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62-9.
26. Tsai C-J, Leitzmann MF, Willett WC, Giovannucci EL. Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol 2008;103:2932-9.
27. Liu C-J. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27:1555-60.
28. Zarrinpar A, Loomba R. The emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909-21.
29. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci 2011;121:43-55.
30. Picchi A, Capobianco S, Qiu T, Focardi M, Zou X, Cao J-M, et al. Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol 2010;2:377-90.
31. Prasad A, Bekker P, Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev 2012;20:177-83.